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Introduction: Many Luminal breast cancers are heterogeneous, containing substantial numbers of estrogen (ER)
and progesterone (PR) receptor-negative cells among the ER+ PR+ ones. One such subpopulation we call “Luminobasal”
is ER-, PR- and cytokeratin 5 (CK5)-positive. It is not targeted for treatment.
Methods: To address the relationships between ER+PR+CK5– and ER–PR–CK5+ cells in Luminal cancers and tightly
control their ratios we generated isogenic pure Luminal (pLUM) and pure Luminobasal (pLB) cells from the same
parental Luminal human breast cancer cell line. We used high-throughput screening to identify pLB-specific drugs and
examined their efficacy alone and in combination with hormone therapy in mixed-cell tumor models.
Results: We show that pLUM and MCF7 cells suppress proliferation of pLB cells in mixed-cell 3D colonies in vitro and
that pLUM cells suppress growth of pLB cells in mixed-cell xenografts in vivo. High-throughput screening of 89
FDA-approved oncology drugs shows that pLB cells are sensitive to monotherapy with the epidermal growth factor
receptor (EGFR) inhibitors gefitinib and erlotinib. By exploiting mixed-cell 3D colonies and mixed-cell solid mouse
tumors models we demonstrate that combination therapy with gefitinib plus the anti-estrogen fulvestrant constitutes a
robust treatment strategy.
Conclusions: We propose that response to combination endocrine/EGFR inhibitor therapies in heterogeneous Luminal
cancers may improve long-term survival in patients whose primary tumors have been preselected for appropriate
biomarkers, including ER, PR, CK5 and EGFR.Introduction
Approximately 75% of breast cancers are luminal. They
express estrogen receptors (ER) and/or progesterone re-
ceptors (PR) [1], tend to be hormone-dependent and are
usually responsive to ER-targeted therapies [2]. Recently
a review of immunohistochemical (IHC) ER and PR as-
says concluded that luminal cancers should be candi-
dates for endocrine therapies if at least 1% of malignant* Correspondence: Allison.scaling@ucdenver.edu
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unless otherwise stated.cells are immunoreactive [3]. We asked: in such cases what
are the other 99%, presumably receptor-negative, malignant
cells? Indeed, the same question applies to less extreme tu-
mors. The ER frequency distribution in 825 sequential
breast cancers over a 2-year period [4] shows that although
81% of tumors are ER-positive (ER+), 30% to 80% of their
cells are ER-negative (ER–). Analyses of 1,235 breast can-
cers [5] show PR distribution to be even more varied, with
approximately 50% of PR+ tumors containing a significant
proportion of PR– cells. Thus, most luminal tumors exhibit
intratumoral heterogeneity containing substantial numbers
of ER– and PR– cells among the ER+ and/or PR+ ones.
Intertumoral heterogeneity is well-known with breast can-
cer subtypes classified based on clinical and histopathologicald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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defined by gene profiling include luminal, human epider-
mal growth factor receptor-2-positive (HER2+) and basal-
like. However, routine gene profiling is limited [7], and as
all transcripts are pooled, the assay does not lend itself to
analysis of intratumoral heterogeneity. Instead, five pro-
tein markers - ER, PR, HER2, Cytokeratin 5 (CK5) and
epidermal growth factor receptor-1 (EGFR) - can serve as
surrogates to classify breast cancers into subtypes analo-
gous to those defined by gene profiling. Using these
markers, IHC analysis of 10,159 invasive breast cancers
collected from 12 studies [8] showed that in addition to
77% of tumors classified as luminal based on ER and/or
PR positivity, approximately 6% are non-luminal but over-
express HER2 protein or its amplified gene [9], and ap-
proximately 16% are basal-like or triple-negative (TN)
because they lack ER, PR and HER2. TN tumors were fur-
ther subclassified into approximately 9% CK5+ and/or
EGFR+ and approximately 7% were negative for all five
markers. Clearly, such detailed intertumoral classification
is important because each subtype responds differently to
endocrine-, immuno- or chemotherapies, and each has a
different long-term fate, with basal-like tumors generally
characterized by heightened aggressiveness compared to
luminal or HER2+ tumors.
Theories on the origins of intra- and intertumoral het-
erogeneity [10] include: rise of subclones from precursors
that subsequently accrue genetic changes; stochastic gene
expression patterns generating random signaling pulses; or
cellular reprogramming by semi-stable imprinting of epi-
genetic tags [11]. The evolution and population frequency
of modified subclones would then be regulated by the age
and diagnostic stage of the tumor, differential growth rates,
microenvironmental signals, cell-cell interaction dynam-
ics, therapeutic interventions, and the like. There is
also speculation based in part on the tissue organization
of normal breast epithelium into luminal and basal ele-
ments, that the origins of intertumoral heterogeneity
might be traced to normal stem cells that underlie these
structures. If so, perhaps as also hinted at by expression
profiling, one might speculate that the two major breast
cancer subtypes - luminal and basal-like - should have
negligible genomic kinship.
We find however, that the distinctions between intra-
and intertumoral heterogeneity are not clear-cut. Recently
we analyzed a series of luminal breast cancers using two
markers - luminal PR and basal CK5 [12]. Four theoretical
cell populations are possible and all were observed:
PR+CK5– cells (luminal); PR–CK5+ cells (we dubbed lumi-
nobasal); cells lacking both markers (double-negative); and
rare PR+CK5+ cells (double-positive). We also observed
that more than 50% of luminal cancers contain luminobasal
cells; that neoadjuvant endocrine therapies increase
luminobasal-cell number in both hormone-responsive andhormone-resistant patients; and that in experimental
models luminobasal-cell expansion can be blocked by
inhibition of Notch signaling [13]. In retrospect, resist-
ance of luminobasal cells to endocrine therapies is not sur-
prising as they lack ER and PR and cluster with basal-like
tumors. These facts suggested to us that presence of lumi-
nobasal cells in luminal disease might be dangerous and
they needed to be targeted for treatment.
To define relationships between luminal and luminobasal
cells and assess the therapeutic vulnerabilities of luminobasal
cells, we have generated pure luminal (pLUM; ER+
PR+CK5–) and pure luminobasal (pLB; ER–PR–CK5+) cell
lines derived from solid T47Dco tumor xenografts. We
characterize them, describe their biological properties when
pure or mixed in three-dimensional colonies or as solid
tumor xenografts, and use high-throughput screening to
demonstrate that the pLB subpopulation is sensitive to EGFR
inhibitors (EGFRi). We demonstrate that simultaneously tar-
geting pLUM and pLB in mixed-cell tumors in vivo and
three-dimensional colonies in vitro with a combination of
the anti-ER fulvestrant plus the EGFRi gefitinib may consti-
tute a robust treatment strategy for heterogeneous primary
luminal disease expressing the appropriate biomarkers.
Methods
Cell lines
MCF-7 human breast cancer cells were from Sam Brooks
(Michigan Cancer Foundation, Detroit); T47D cells were
from Iafa Keydar (Tel Aviv University, Israel); the T47Dco
subline was described in Horwitz et al. [14]. All cell lines
have been authenticated by STR analysis and are
mycoplasma-free.
Generation of pLUM and pLB
All animal studies were approved by the University of
Colorado Institutional Animal Care and Use Committee
(approval number 91212 (02) 1E). Briefly, wild-type T47Dco
cells in Matrigel were injected into cleared mammary fat
pads of pre-pubertal ovariectomized (ovx’d) NOD SCIDγ
(NSG) mice (NCI, Frederick, MD, USA or Jackson Labora-
tories, Bar Harbor, ME, USA) and implanted with cellulose
(E withdrawn, EWD), 2 μg 17β-estradiol (E), or E + 8 μg pro-
gesterone (E + P)-containing pellets [13]. Three-month old
tumors were minced, rotated with collagenase, DNAse and
hyaluronidase followed by red blood cell lysis. Cells were
plated in phenol-red free DMEM (Gibco) containing 5%
charcoal-stripped fetal bovine serum (FBS) in EWD or
1 nM E-supplemented conditions.
To generate pLUM, cells from an E-tumor were propa-
gated in vitro for approximately 2 months in 1 nM E. Live
cells were sorted by fluorescence-activated cell sorting
(FACS) (Moflo XDP 100, Beckman Coulter, Indianapolis,
IN, USA) using CLD3 and CD49f to separate luminal
(CLD3+ CD49f–) from luminobasal (CLD3– CD49f+) cells.
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approximately 2 months more in E and re-sorted twice to
generate pure pLUM (CLD3+ CD49f–). They were main-
tained in E-containing medium and remained luminobasal-
free. To generate pLB, cells from an E + P tumor were
plated in vitro for approximately 2.5 months under EWD
conditions. They were sorted by FACS and the CLD3–
CD49f + subpopulation was re-cultured for approximately
2 months more under EWD conditions then re-sorted twice
to yield pure pLB (CLD3– CD49f+). They were main-
tained in EWD media and remained luminal-free. Both
cell lines were authenticated by STR and are mycoplasma-
free. Maintenance of pLUM and pLB states is monitored
by IHC for a series of marker proteins (Table 1). Aliquots
have been stably tagged with ZsGreen (ZsG) fluor [15].
Expression profiling
Briefly [16], 72 h 1 nM E-treated pLUM; EWD pLB; and
E plus 100 nM P-treated T47Dco cells were suspended
(Accumax; Millipore, Billerica, MA, USA), fixed, perme-
abilized with RNAlater (Ambion Inc., Ambion, Foster City,
CA, USA) and incubated with anti-CK5 labeled with Zenon
Alexa Fluor 488 (Invitrogen, Grand Island, NY, USA;
Z-25002). Stained cells were centrifuged and resuspended in
RNAse-free NST buffer containing 4′,6-diamidino-2-pheny-
lindole (DAPI), and CK5+ versus CK5– cells sorted by
FACS (Beckman-Coulter XDP-100 MoFlo). Separated cellsTable 1 Characterization of pure luminobasal (pLB) and
pure luminal (pLUM) cells
Immunohistochemistry mRNA
Factors pLB pLUM Fold pLB versus pLUM
CK5 +++ - + 7,336
Jag1 + - + 809
Annexin A1 +++ + + 405
EGFR ++ - + 146
Slug (SNAI2) + - + 103
p63 (TP63) ++ - + 65
CD49f (Itga6) +++ - + 23
p-Cadherin (CDH3) ++ - + 20
Notch-1 + - + 8
CD44 ++ - + 1.3
CK8/18 + +++ - 3
FOXA1 - ++ - 5
GATA3 - ++ - 46
ER - ++ - 70
Claudin-3 - ++ - 113
Muc1 - ++ - 118
PR - ++ - 189
CK5, cytokeratin 5; EGFR, epidermal growth factor receptor; ER, estrogen
receptor; PR, progesterone receptor.were collected, centrifuged, and resuspended, and RNA was
extracted (PicoPure; Arcturus/Life Technologies, Carlsbad,
CA, USA). RNA from triplicate sorts was profiled using Agi-
lent 4 × 44 K chips. Labeling, hybridization and initial ana-
lyses were performed at MOGENE LC, St. Louis, MO, USA.
All microarray data can be accessed in the Gene Expression
Omnibus database [GSE55350; GEO].
Mixed-cell xenografts
pLUM (5 × 105), ZsG-pLB alone, or 5:1 mixtures of pLUM:
ZsG-pLB in Matrigel were injected into cleared mammary
fat pads of ovx’d NSG mice implanted with cellulose
(EWD) or E pellets. Tumor growth was quantified weekly
for 8 weeks. At necropsy, tumors were resected, fixed in
4% paraformaldehyde, paraffin-embedded and processed
for IHC. Paraffin sections were stained with DAPI, tumor
boundaries were defined, scanned for ZsG fluorescence
(Nikon T1 Eclipse) and quantified (NIS-Elements software;
Nikon, Melville, NY, USA). For combination therapy ex-
periments, 5 × 105 pLUM, pLB alone, or 1:1 pLUM:pLB
mixtures in Matrigel were injected as described above.
Control 6 wk-old tumors generated from 1:1 mixtures
were treated for 10 days with vehicles, gefitinib (100 mg/kg
daily in 1% Tween; oral gavage), Fulvestrant (50 mg/mouse
on days 1 and 6 in 10% ethanol and sesame oil; subcutane-
ously), or both. Tumor volumes were quantified every
48 h.
Mixed cells in vitro
pLB (5 × 104) or pLUM alone, or as 5:1, 3:1, 1:1, 1:3 or 1:5
pLUM:pLB ratios, were plated in E-free, growth factor
(GF)-reduced Matrigel and grown into three-dimensional
colonies for 7 days [17]. Alternatively, pLUM, pLB and
MCF7 cells alone or as 1:1 or 5:1 pLUM:pLB or MCF7:pLB
ratios were established over 24 h then treated for 7 days
with: a) vehicles; b) 100 nM fulvestrant; c) 1 μM gefitinib
on days 6 and 7; or d) fulvestrant plus gefitinib on days 6
and 7. Colonies were incubated for 1 h with bromodeox-
yuridine (BrdU; Sigma, St. Louis, MO, USA), and Matrigel
blocks were sandwiched between HistoGel, paraffin-
embedded and sectioned for IHC [17].
Immunohistochemistry (IHC)
Serial 4-μm sections were stained by dual IHC and DAPI
for relevant luminal, basal, luminobasal and proliferation
markers. Antibodies and sources are listed in Additional
file 1: Table S1. Sections were photographed (Nikon Eclipse
E600 fluorescence microscope) and cell subpopulations
quantified (Image Pro 4.5; Media Cybernetics, Rockville,
MD, USA). A BrdU index (BrdU+ nuclei in CK5+ or CK5–
cells versus DAPI+ nuclei) was calculated from five
random 100× (three-dimensional colonies) or 400×
(xenografts) fields/condition.
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Cell-free (C) or pLB, pLUM or MCF7 cells were cul-
tured to 50% to 60% confluence in DMEM with 5%
FBS, then washed and incubated for 48 h in phenol red-
free DMEM and charcoal-stripped FBS. Conditioned
media (CM) were purged of cellular elements by filtra-
tion (0.2 μM). Separately, cells were grown for 48 h as
three-dimensional Matrigel colonies in multiwall cham-
bers. Medium was discarded and colonies were re-
incubated with C or CM for an additional 48 h. Unfixed
colonies were photographed (Nikon Eclipse E600) and
cluster diameters were quantified from 100× brightfield
images (Nikon NIS Elements).
High-throughput drug screening
Mixtures (1:1) of ZsG-pLB (104) and untagged pLUM (104)
were cultured for 24 h in triplicate 96-well plates in EWD or
2 nM+E conditions, then treated for 48 h with 0.05%
DMSO or 1 μM drug from the 89-drug NCI-DTPApproved
Oncology library (Additional file 2: Table S2). Media were
aspirated, cells were fixed and immunostained with anti-
CLD3, and counterstained with DAPI. Total (blue), pLUM
(red) or pLB (green) subpopulations were imaged and quan-
tified at 20×. Nine fields/well were captured (Additional
file 3: Figure S1) averaging 8,000 cells/field in controls.
Statistical analysis
Data were quantified as the mean ± standard error (SEM)
of three or more separate experiments, and analyzed with
Prism 6.0 (Graphpad Software, Lo Jolla, CA, USA) using
one way analysis of variance (ANOVA) or Student’s t-test.
Differences with P ≤0.05 were considered to be significant.Figure 1 Fluorescence-activated cell sorting (FACS) purification of pu
Left panel: FACS of a mixed-cell T47Dco xenograft isolated from an estroge
isothiocyanate (FITC) (x-axis) and CD49f-PE-CY5 (y-axis), showing both c
separately collected and expanded in culture; cell lines were derived aResults
Generation of pLUM and pLB cells
We recently isolated two cell lines from luminal T47Dco
xenografts grown in ovx’d NSG mice: EWD8 consisting
mainly of luminobasal ER–PR–CK5+ cells derived from a
tumor in EWD mice; and E3 consisting mainly of luminal
ER+PR+CK5– cells derived from a tumor in E-
replenished mice [13]. Gene profiling, confirmed by IHC
showed that CD49f expression was unique to EWD8 and
CLD3 expression was unique to E3 [13]. Antibodies
against these two proteins were used here for sequential
dual FACS of another set of T47Dco mouse tumor-
derived cells to generate two new, isogenic, pure cell lines:
pLB are CLD3– CD49f+ and ER–PR–CK5+; pLUM are
CLD3+ CD49f– and ER+PR+CK5– (Figure 1). Despite
originating from the same parental cells each line exhibits
a distinct gene signature (Additional file 4: Figure S2). pLB
cells are propagated in vitro under EWD conditions;
pLUM cells are propagated under E-replete conditions.
Both have been tagged with ZsGreen [18].
To confirm markers unique to pLB or pLUM, expres-
sion of a 17-protein subset selected from the luminoba-
sal gene signature [13] was assessed by IHC (Table 1).
Proteins that marked pLB but not pLUM include CK5,
Jag1, AnnexinA1, EGFR, Slug, p63 and CD49f; proteins
that marked pLUM but not pLB include ER, PR, MUC1,
CLD3, GATA3 and FOXA1. This confirms gene profiling
transcript data (Table 1), the luminal assignment of pLUM,
and the luminobasal assignment of pLB, which cluster with
basal cells and tumors [13] but retain luminal markers like
CK8/18. Like their parental cells, neither pLUM nor pLB
express HER2 protein (not shown).re luminal (pLUM) versus pure luminobasal (pLB) subpopulations.
n (E) + progesterone (P) treated mouse, using CLD3- fluorescein
ell populations. pLB (right panel) and pLUM (center panel) were
fter re-sorting.
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pLB cells
Most luminal tumors are heterogeneous, composed of
cell mixtures including ER–PR–CK5+ luminobasal cells
[12]. Because in TN disease luminobasal-like cells are





































Figure 2 Pure luminal (pLUM) suppress proliferation of
neighboring pure luminobasal (pLB) in mixed-cell xenografted
solid tumors. (A) Whole-tumor cross-sections of untagged pLUM,
ZsGreen (ZsG)-pLB and 5:1 pLUM:pLB xenografts grown in
ovariectomized mice without hormones. Tumor sections counterstained
with 4′,6-diamidino-2-phenylindole (DAPI) (blue). Scale bars equal
2000 μM. (B) Quantitation of ZsG fluorescence in pLUM, pLB and 5:1
pLUM:ZsG-pLB tumors relative to fluorescence of pure ZsG-pLB tumors
under control (C) or estrogen (E) conditions. (C) Proliferation rates
quantified by bromodeoxyuridine (BrdU) incorporation of pLUM and
ZsG-pLB subpopulations in pure and mixed-cell tumor xenografts.
Percent BrdU + cells in CK5– and CK5+ cells were quantified for ≥5
independent tumors; *P ≤0.05.tumors the pLB subpopulation would eventually become
dominant. However, in both luminal disease and in vitro
models, ER–PR–CK5+ cells are indolent; proliferating
more slowly than their ER+PR+CK5– neighbors [12]. To
show if pLUM cells suppress nearby pLB cells the pure
cell lines were used to control the ratio of each subpopula-
tion in mixed-cell xenografts. Figure 2 shows data for 8-
week-old tumors grown from pLUM, ZsG-pLB or a 5:1
pLUM:ZsG-pLB mixture in ovx’d mice without (C) or
with E supplementation. The pure cell lines yield relatively
pure tumors (green pLB or untagged pLUM) of each cell
type (Figure 2A). However regardless of the hormonal
state (Figure 2A, B) in 5:1 mixed pLUM:ZsG-pLB im-
plants, the number of green pLB cells was significantly
(P = 0.0164) suppressed. Despite starting at 20% of the
population, only 4% to 8% of cells were pLB at necropsy
(Figure 2B). Mixed-cell tumors tended to enlarge rapidly
but had extensive necrotic centers and the rare pLB cells
aggregated to tumor fringes (Figure 2A). Evidence for pLB
suppression by pLUM cells was confirmed by BrdU quan-
titation (Figure 2C) showing that even in the absence of E
(conditions in which luminal cells are unstimulated) pLUM
cells suppress pLB proliferation.
Mixed cells in vitro
To address mechanisms for pLB suppression by pLUM,
single-cell suspensions of pLUM and pLB cells either alone
or mixed in pLUM:pLB 5:1, 3:1, 1:1, 1:3 or 1:5 ratios were
grown as three-dimensional colonies under EWD condi-
tions [17]. Seven-day colonies were incubated with BrdU,
sectioned and dual-stained for BrdU plus luminal CK8/18
or basal CK5 to mark each subpopulation (Figure 3). Note
that despite having been introduced into Matrigel co-
mingled, cells aggregate by type with mixed-cell colonies
characteristically having a pLB core surrounded by pLUM
(Figure 3A, top). In general, pLUM cells have a higher pro-
liferation rate than pLB cells (Figure 3A bottom, B), and
pLB proliferation progressively shrinks as the proportion
of pLUM rises (Figure 3B). At 5:1 pLUM:pLB ratios pro-
liferation of pLB is reduced by approximately 81%
(P <0.0001) compared to pLB controls.
To demonstrate that suppression by pLUM of pLB is a
general phenomenon, the three-dimensional mixed-cell
colony assay was repeated substituting classic luminal
ER+PR+ MCF-7 cells for pLUM (Figure 3C). MCF-7
cells are powerful suppressors, progressively reducing
pLB proliferation with 97% (P <0.0001) pLB suppression
at the 5:1 MCF-7:pLB excess.
As mixed cells segregate by subtype within colonies
and tumors with minimal direct pLUM and pLB cell-cell
contact, we speculated that pLUM suppress pLB via a
diffusible factor. To test this, pLB, pLUM or MCF-7 cells
growing as three-dimensional colonies were incubated
with media previously conditioned (CM) by pLB, pLUM

















































































































Figure 3 Pure luminobasal (pLB) proliferation is suppressed by
pure luminal (pLUM) cells via a diffusible factor. pLUM, pLB and
ratios of pLUM:pLB cell mixtures were seeded onto solidified growth
factor (GF)-reduced Matrigel. Three-dimensional colonies were
cultured for 7 days in hormone-free conditions. Bromodeoxyuridine
(BrdU) was added, Matrigel blocks were sandwiched between
HistoGel, paraffin-embedded and sectioned for immunohistochemistry
(IHC). (A) Sections dual stained for CK5 (red) and CK8/18 or BrdU
(green), counterstained with 4',6-diamidino-2-phenylindole (DAPI)
(blue). Scale bars equal 20 μM. (B) Quantitation of BrdU incorporation
into pLB or pLUM cells in pure cells (set at 100%) or mixed-cell colonies.
(C) Same as A and B, but MCF-7 were substituted for pLUM.
(D) Media-conditioned (CM) by no cells (control), or by pLB, pLUM or
MCF7 cells growing in 2D on plastic, were collected. Separately, pLB,
pLUM or MCF-7 cells were grown as three-dimensional Matrigel
colonies in regular media for 48 h, then switched to the CM media
shown for 48 h. Colonies were photographed and their diameters in
CM were compared to colony diameters in control media; *P ≤0.05;
**P ≤0.01; ***P ≤0.001; ****P ≤0.0001.
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cell-free medium, pLUM (Figure 3D) or MCF-7 CM (not
shown) significantly reduced the size of pLB colonies by
>50% (P <0.0001) whereas pLB CM had little effect on
pLUM or MCF-7 (Figure 3D) colonies. This suggests that
diffusible inhibitory factor(s) released by luminal cells sup-
press proliferation of nearby luminobasal cells.
pLB cells are selectively targeted by EGFR inhibitors
In mixed-cell hormone-dependent tumors, luminobasal
cells are intrinsically hormone- and chemotherapy-resistant
[12,13]. This scenario may be acceptable in untreated
cancers containing few luminobasal cells. The danger arises
when the number of luminobasal cells expands as ER-
targeted therapies reduce luminal cell number [12].
We therefore suspect that luminobasal cells should be
treated in primary tumors. To identify drugs that select-
ively do so, the 89-drug NCI-DTP Approved Oncology li-
brary (Additional file 2: Table S2) was screened. It contains
hormone antagonists, chemotherapeutic agents, target-
based kinase inhibitors and epigenetic/histone acetylation-
modifying drugs in current clinical use. A high-throughput
screen used fluorescent imaging to quantify ZsG-pLB cells
and CLD3+ pLUM cells plated in 1:1 mixtures. Cells
were pretreated for 24 h under EWD or +E conditions
(Additional file 3: Figure S1), after which pLB comprised
45% of cells in EWD wells and 39% in +E wells. While
EWD or +E were continued, the cells were exposed to
drugs for 48 h. Figure 4A summarizes the number of pLB
(red), pLUM (green) and % pLB (black) compared to ve-
hicle controls under +E conditions. Extensive nonspecific
cytotoxicity for both cell types was induced by chemother-
apeutic agents such as vincristine, azacytidine, gemcitabine,
mithramycin, et cetera. However, selective and targeted
reduction of the pLB subpopulation (note the drop in %
black pLB bars with conservation of green pLUM bars)
Figure 4 (See legend on next page.)
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Figure 4 High-throughput screening: targeting pure luminobasal (pLB) cells with drugs from an NCI-approved 89-drug oncology library.
(A) 1:1 mixtures of pLUM:ZsG-pLB were co-cultured in triplicate 96-well plates in 1 nM 17β-Estradiol (E; not shown, see panel B) or E-free (shown) con-
ditions, then treated 48 h with a panel of 89 NCI-approved oncology drugs (1 μM) or 0.05% dimethyl sulfoxide (DMSO) controls. Media were aspirated,
cells were fixed, immunostained for CLD3 (red) and counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue). Total (blue), pure luminal (pLUM)
(red) or pLB (ZsG, green) subpopulations were imaged and quantified at 20×. There were 9 fields/well captured, averaging 8,000 cells/field in controls
(Additional file 3: Figure S1A). Mean numbers of pLB (red bars) and pLUM (green bars) cells, and % pLB (black bars) are shown as the average of tripli-
cates ± standard error of the mean (SEM). Erlotinib, P ≤0.0001, gefitinib, P = 0.0005. (B) Details of vehicle, erlotinib or gefitinib data from panel A in both
+E and –E conditions; ***P ≤0.001; ****P ≤0.0001 for pLB cell numbers in gefitinib or erlotinib versus vehicle control.
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gefitinib and erlotinib (Figure 4A). Detailed analyses under
both EWD and +E conditions (Figure 4B) showed that after
48 h gefitinib reduced the pLB subpopulation from 45% to
9% (EWD) (P ≤0.0001) and from 39% to 9% (+E) (P =
0.0005). Similarly, erlotinib reduced the pLB subpopulation
to 10% (EWD) (P = 0.0001) and 7% (+E) (P ≤0.0001). Nei-
ther drug influences the pLUM subpopulation.
The reliance on EGFR signaling correlates with upregula-
tion of EGFR in pLB cells [13] (Table 1; Additional file 5:
Figure S3). Interestingly, during the 48 h treatment time
the dual HER2/EGFR inhibitor lapatinib, currently in use
for second-line therapy of herceptin-resistant ER+EGFR+
HER2+ breast cancers, did not reduce the pLB subpopula-
tion, consistent with the fact that HER2– tumors (like pLB)
tend to be unresponsive to this drug [19]. Additionally, nilo-
tinib, a bcr-abl inhibitor produced an unexpected and sig-
nificant increase in the proportion of pLB cells, an effect
that requires further study. Lastly, the pLUM subpopula-
tion was unaffected by the endocrine therapeutic
drugs present in the library. In our experience, in 2D con-
ditions like those used here these require a longer treat-
ment window (but see 3D, Additional file 6: Figure S4).
Combination anti-ER/anti-EGFR therapy targets both
populations in mixed-cell tumors
Our goal is to proffer combination therapies that target
luminal and luminobasal subpopulations in heterogeneous
ER+PR+disease. We tested gefitinib in combination with ful-
vestrant (ICI 182, 780; ICI) using 1:1 or 5:1 pLUM:ZsG-pLB
mixtures in three-dimensional colonies (Figures 5, Additional
file 6: Figure S4A) treated with vehicle, ICI (100 nM), gefitinib
(1 μM) or ICI + gefitinib. BrdU was added prior to harvest,
colonies were fixed, sectioned and stained for CLD3, CK5 and
BrdU, photographed and a BrdU index/cell type was quanti-
fied. Gefitinib completely suppressed pLB proliferation with
no effect on pLUM. ICI significantly reduced pLUM with no
significant effect on pLB. Combining the drugs showed no in-
fluence of one on the other (Figure 5A). Drug effects in 1:1
and 5:1 pLUM:pLB colonies were highly effective: the combin-
ation decreased proliferation in 1:1 pLUM:pLB colonies by
88.5% (P <0.0001), and in 5:1 colonies by 95% (P <0.001).
Additionally the cell heterogeneity exposed effects of one cell
type on the other. For example, suppression of pLUM by ICI
monotherapy paradoxically increased pLB proliferation in theabsence of gefitinib by removing the pLUM-secreted inhibitor
(Figure 3). We argue that this can be prevented in cell mix-
tures by combination therapies that target both cell types. In
sum the data point to the value of targeting two cell subpop-
ulations in a tumor, and provide an illustration that mono-
therapy targeting one subpopulation, can have the
unintended consequence of allowing the other to expand.
To demonstrate that this outcome was not restricted to
one cell line, we substituted MCF-7 cells for pLUM cells
(Figure 5B). This shows again the marked suppressive ef-
fects of MCF-7 cells on proliferation of neighboring pLB
cells even without treatment, the further proliferative sup-
pression of pLB by gefitinib, and the efficacy of the com-
bination therapy in reducing overall colony cell growth.
Photographs of representative colonies stained for CK5
(red), BrdU (green) and total cells (blue) are shown for
pLUM:pLB (Additional file 6: Figure S4A) and MCF-7:
pLB (Additional file 6: Figure S4B). Note for example that
gefitinib completely shuts down proliferation of pure pLB
colonies (panel 5); or that only luminal cells in mixed col-
onies proliferate with combination therapies (panel 16).
We then tested a gefitinib/ICI combination in heteroge-
neous solid tumors in vivo (Figure 5C). For this 5 × 105
pLUM, pLB or a 1:1 pLUM:pLB mixture was injected into
cleared mammary fat pads of ovx’d mice without hormone
supplementation and grown into tumors for 6 weeks. Since
pLUM cells suppress pLB cells (Figures 2 and 3) the 1:1 ra-
tio was chosen so that sufficient numbers of pLB cells
would remain in 6-week-old tumors to allow their quanti-
tation despite further EGFRi suppression. Six-week tumor-
bearing mice were administered vehicle controls, ICI
(5 mg/mouse; days 6 + 10), gefitinib (100 mg/kg, once
daily), or ICI + gefitinib for 10 days. Tumor sizes were mea-
sured every 48 h. Tumors continued to expand in controls
during 10 days; they were modestly reduced by ICI (which
requires longer treatment times) and significantly reduced
by gefitinib alone (P = .0005) or the gefitinib + ICI combin-
ation (P = .0002). These data demonstrate that EGFRi can
target LB cells even in the presence of an anti-estrogen.
Discussion
Hormone resistance
Treatments for luminal breast cancer exploit its ER-
positivity and estrogen dependence by disrupting estrogen
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Figure 5 (See legend on next page.)
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Figure 5 Combined targeting of pure and mixed-cell pure luminal (pLUM) and pure luminobasal (pLB) colonies with fulvestrant/gefitinib. (A)
Pure pLUM, pLB or 1:1 and 5:1 pLUM:pLB mixtures were grown as three-dimensional Matrigel colonies in the absence of hormones for 48 h. Colonies were
switched for 5 days to media containing no drug (days 1 to 5); 1 uM gefitinib (days 4 to 5); 100 nM ICI (days 1 to 5); or both (ICI days 1 to 5; gefitinib days
4 + 5). Colonies were treated with bromodeoxyuridine (BrdU), processed for immunohistochemistry (IHC) and a BrdU proliferation index was quantified.
Data are average of triplicates ± standard error of the mean (SEM). *P ≤0.05; **P ≤0.01, ***P ≤0.001, ****P ≤0.0001, ns, not-significant. (B) Same as A
except MCF-7 cells were substituted for pLUM. (C) 1:1 mix of pLUM:pLB cells was injected into cleared fat pads of ovariectomized non-obese
diabetic/severe combined immunodeficient (NSG) mice and tumors were grown 6 weeks without hormones. Mice were treated 10 days with no drug
(Control), fulvestrant (ICI), gefitinib or both. Tumor volumes are expressed as % volume on treatment day 0, for ≥4 tumors ± SEM at each time point.
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long-term survival declines steadily after 5 years and eventu-
ally falls below that of basal-like cancers [20,21]. Mecha-
nisms underlying luminal tumor recurrence are varied.
Explanations include development of acquired resistance
through genetic or epigenetic pathways that target ER sig-
naling or upregulate growth factor escape, or pre-existing re-
sistance due, for example, to mutant ER [22]. All likely apply
to subsets of patients. However, directly or indirectly all as-
sume that ER+ cells - either early or late in luminal tumor
evolution - undergo the molecular changes linked to resist-
ance. The present study focused on an alternative mechan-
ism, namely that many primary luminal tumors are
heterogeneous at diagnosis, containing ER– cells that lack
the molecular machinery to respond to endocrine therapies.
Although the origins of ER– cells in luminal disease remain
under intense study [23], we argue that such cells cannot be
ignored and should be treated along with their ER+ neigh-
bors. Indeed we have shown in both clinical and experimen-
tal settings that targeting only the ER+ subpopulation has
the unintended consequence of increasing the ER– subpop-
ulation, perhaps spawning acquired heterogeneity. Our goal
here has been to discover drugs for treatment of luminal
cancers that would suppress the intrinsic or acquired
ER–PR–CK5+ subpopulation when combined with
standard endocrine therapies. For that we needed pure
luminal-derived ER–PR–CK5+ cells for drug screening,
that is, the pLB cells reported here (Figure 1).
Luminal tumor-cell heterogeneity
Assessment of intratumoral heterogeneity requires cell-
by-cell or microdissection methods that do not assume a
tumor is a uniform mass of identical cells. This is in
contrast to studies using bulk tumor DNA, RNA or pro-
tein for analysis of gene expression patterns, mutation
spectra, copy number changes, et cetera. [24]. Although
the latter clearly show that even within major breast
cancer subtypes like luminal there are clinically import-
ant subsets that modify patient outcome and necessitate
unique therapeutic approaches, they do not address intra-
tumoral cell heterogeneity. Some studies have used laser
capture microdissection to demonstrate intratumoral cyto-
genetic heterogeneity [25], or heterogeneity of c-myc,
cyclinD1 [26], HER2 [27] or ER [28] expression. We usedER/PR and CK5 as markers to show that significant cellu-
lar variability exists within and between luminal tumors
[12] with ER–PR–CK5+ cells interspersed among the
ER+PR+CK5– cells in more than 50% of cases. Clearly this
presents significant diagnostic and therapeutic challenges,
including the risk of flawed prognostic estimates and inad-
equate treatment based on reliance on a single, possibly
unrepresentative, biopsy. Transcending these is the failure
to treat subpopulations of tumor cells that are not identi-
fied by current assays [23,29-31].
Modeling luminal heterogeneity
Here we developed pure ER+PR+CK5– and ER–PR–CK5+
cell lines derived from the same parental luminal precursor
that allow us to reconstruct intratumoral heterogeneity
while tightly controlling the ratio of these two cell popula-
tions. Among other things, we needed to control luminoba-
sal cell numbers because they are often sparse in untreated
mixed-cell luminal cancers. Additionally, although the ori-
gins of intratumoral heterogeneity remain unclear, with
both cancer stem cell and clonal evolution hypotheses prof-
fered, in either scenario cell variability is posited to originate
from a single cell [29]. This renders the progeny genetically
identical. We sought to model this property as well. To our
knowledge pLUM and pLB represent rare examples of nat-
ural isogenic cells exhibiting substantive phenotypic differ-
ences. To generate them, fixed CK5– and CK5+ cells
sorted by FACS from the same tumor xenograft were pro-
filed to discover genes that encode cell-surface proteins and
discriminate between the two populations [13]. This
allowed us to develop a novel FACS-based scheme using
CLD3 and CD49f to separate the two cells from a parental-
cell mixture in a sterile, live state (Figure 1). Successive pu-
rifications yielded highly pure cell lines that maintain
pLUM or pLB phenotypes in culture and provide a stable
resource for modeling and manipulating heterogeneity. As
the cells share a common progenitor and exhibit little gen-
etic divergence [13] this limits the influence of unique mu-
tations on their biological behavior and response to drugs.
Luminal cells suppress luminobasal cells
Clinical evidence [12], in vitro three-dimensional colonies
(Figure 3) and in vivo solid tumor xenografts (Figure 2)
demonstrate that luminal and luminobasal cells in a
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same cells in pure states, suggesting that there is cross-
talk between them. Heterogeneous mixed-cell xenografts
are larger but more necrotic than their homogenous pure-
cell counterparts (Figure 2). In mixed three-dimensional
colonies, pLUM proliferation is stimulated by presence of
pLB cells (Figure 3) or by LB-conditioned media (Figure 3D).
The soluble factors involved are unknown but could in-
clude insulin-like growth factors known to be high in ER–
cells, low or absent in ER+ cells, but induce ER and
promote ER+ tumor growth [32,33]. In contrast pLB cell
proliferation is suppressed by neighboring pLUM or
MCF7 cells (Figure 3), which also involves secreted factors
(Figure 3D). The paracrine-acting inhibitory factors are
also unknown but could include transforming growth fac-
tor (TGF)-β [34,35]. The findings of LB suppression by
LUM, plus our clinical data showing that luminobasal cells
are upregulated in tumors of tamoxifen-treated patients
[12] present a troubling scenario. Namely, that prior
to antiestrogen therapy a minor intrinsic luminobasal
subpopulation is suppressed by dominant neighboring
luminal cells. However, as antiestrogens shrink inhibitory
signals coming from the luminal population, the luminoba-
sal population expands; this is an illustration of inadvertent
therapy-induced enrichment [33,36]. These findings under-
score the impact that intratumoral cellular dynamics have
on the success (or failure) of endocrine therapies in hetero-
geneous tumors, prompting us to seek drugs that directly
target the ER–CK5+ subpopulation.
Combination therapy targeting Luminal tumor
heterogeneity
To find drugs that suppress the luminobasal subpopula-
tion, co-cultured pLUM and pLB cells were arrayed and
screened for pLB-specific drugs using a library of 89
FDA-approved and well-characterized oncology thera-
peutics. The two EGFRi in the library, gefitinib and erlo-
tinib, were highly pLB-specific. This was in contrast, for
example, to the EGFR/HER2 inhibitor lapatinib, which
showed no selectivity (Figure 4 and Additional file 2:
Table S2). Identification of EGFRi as luminobasal-specific
agents led us to analyze a dual antiestrogen/EGFRi com-
bination that simultaneously targets pLUM and pLB in
mixed-cell three-dimensional colonies (Figure 5A, 5B) and
xenografts (Figure 5C). We observed a strong response to
brief gefitinib treatment, even in the presence of fulves-
trant, demonstrating that the EGFRi is bioactive in com-
bination with an antiestrogen.
Clinically, EGFRi monotherapy or antiestrogen/EGFRi
combinations have yielded mixed results. In advanced
luminal disease previously treated with antiestrogens, gefi-
tinib had no detectable benefit, perhaps because the tumors
contained few EGFR+ cells [37]. On the other hand, in
metastatic disease, Cristofanilli et al. observed that gefitinibin conjunction with anastrozole prolonged progression-free
survival [38]. With regard to therapy for early stage disease,
addition of gefitinib to anastrozole failed to improve out-
come in one study [39], while in another, gefitinib com-
bined with tamoxifen was beneficial in previously untreated
patients [40]. Clinical benefits of EGFR inhibition may
stem from delaying acquisition of hormone resistance [38]
or from blocking proliferative growth factor signaling in
tumors with EGFR+ cells. In support of this, neoadjuvant
treatment of primary tumors with gefitinib or gefitinib
plus anastrozole in a postmenopausal, EGFR+ cohort re-
duced proliferation, EGFR activation and tumor size [41].
We propose that response to combination endocrine/EGFRi
therapies in ER+ luminal cancers may improve long-term
survival in patients whose tumors have been preselected
[42] for presence of a luminobasal subpopulation based
on ER/PR, CK5 and EGFR biomarker expression.
Conclusions
Currently, the ER–PR–CK5+ cells of luminal breast cancers
are not treated. They are malignant, indolent and
antiestrogen-resistant; they expand in response to endocrine
or chemotherapies [21]; at least a subset has tumor-
initiating capacity [12,13,43]. We now show that in mixed-
cell experimental models, the ER–PR–CK5+ population can
be suppressed by EGFRi and that combination endocrine/
EGFRi therapies may additively target ER+PR+CK5– and
ER–PR–CK5+ subpopulations. Clinically, luminal breast
cancers exhibiting the appropriate heterogeneity for treat-
ment by this combination could be easily identified using
ER/PR and CK5 or EGFR as biomarkers. As EGFRi are
already approved for oncology use, the combination therap-
ies we propose can be immediately translated to clinical
trials.
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